Trial Condition(s):

Macular Edema

Efficacy and safety of three different aflibercept regimens in subjects with diabetic macular edema (DME) (VIOLET)

Bayer Identifier:

17613

ClinicalTrials.gov Identifier:

NCT02818998

EudraCT Number:

2014-004938-25

EU CT Number:

Not Available

Study Completed

Trial Purpose

To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections for approximately 1 year or more (according to the EU label for the first year of treatment)

Inclusion Criteria
The subject’s history of aflibercept treatment met all of the following:
 - Treatment in the study eye was initiated with five monthly (-1 week /+2 weeks) doses of 2 mg aflibercept and improvements of visual and anatomic outcomes were observed and documented.
 - Following the above initiation phase, the intervals between treatments were between 6 weeks and 12 weeks (one exception was allowed).
 - The interval between the last 2 pre-study injections was ≥ 8 weeks, and visual and anatomic outcomes had been stable over this interval.
 - The subject received the last intravitreal (IVT) injection of aflibercept in the study eye 8 weeks (±10 days) before the first planned treatment /randomization in this study.
 - Total prior treatment duration with aflibercept (i.e. from first aflibercept treatment ever to enrollment into this study) was 1 year or longer.

To be met at initiation of pre-study aflibercept treatment:
 - Type 1 or 2 diabetes mellitus (DM)
 - Diagnosis of diabetic macular edema (DME) secondary to DM involving the center of the macula (defined as the area of the center subfield on optical coherence tomography [OCT]) in the study eye
 - Decrease in vision determined to be primarily the result of DME in the study eye
 - Best corrected visual acuity (BCVA) in the study eye of Early Treatment Diabetic Retinopathy Study (ETDRS) letter score 73 to 24
Exclusion Criteria
At initiation of pre-study aflibercept treatment:
- Previous treatment with anti-angiogenic drugs in study eye (e.g., pegaptanib sodium, bevacizumab, ranibizumab, or aflibercept) within the last 12 weeks before initiation of aflibercept pre-study treatment

At initiation of pre-study aflibercept treatment, screening for this study, and baseline for this study:
- Prior treatment of the study eye with long acting steroids, either periocular or intraocular, in the preceding 120 days or Iluvien intravitreal implant at any time
- Active proliferative diabetic retinopathy, current iris neovascularization, vitreous hemorrhage, or tractional retinal detachment in the study eye
- Cataract surgery or any other intraocular surgery within 90 days of aflibercept treatment in the study eye
- Ocular inflammation (including trace or above) or history of uveitis in the study eye
- Structural damage to the center of the macula in the study eye that was likely to preclude improvement in BCVA following the resolution of macular edema including atrophy of the retinal pigment epithelium, subretinal fibrosis or scar, significant macular ischemia or organized hard exudates
- Concurrent disease in the study eye, other than DME, that could compromise visual acuity, require medical or surgical intervention during the study period, or could confound interpretation of the results (including advanced glaucoma, retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause)
- Uncontrolled DM as defined by hemoglobin (Hb) A1c > 12.0% at screening and baseline for this study
- Any ocular or periocular infection in the preceding 4 weeks in either eye
- History of either cerebral vascular accident and/or myocardial infarction within 180 days before aflibercept treatment

Trial Summary

Enrollment Goal
463
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Darmstadt, Germany, 64297

Status
Completed
Locations

Investigative Site

Köln, Germany, 50924

Status
Completed
Locations

Investigative Site

Göttingen, Germany, 37075

Status
Completed
Locations

Investigative Site

Frankfurt, Germany, 60596

Status
Completed
Locations

Investigative Site

Dresden, Germany, 01307

Status
Completed
Locations

Investigative Site

Bonn, Germany, 53105

Status
Completed
Locations

Investigative Site

Marburg, Germany, 35043

Status
Completed
Locations

Investigative Site

Sherbrooke, Canada, J1G 2V4

Status
Completed
Locations

Investigative Site

Montreal, Canada, H4P 2S4

Status
Completed
Locations

Investigative Site

Halifax, Canada, B3H 2Y9

Status
Completed
Locations

Investigative Site

Toronto, Canada, M3C 0G9

Status
Completed
Locations

Investigative Site

Mississauga, Canada, L4W 1W9

Status
Completed
Locations

Investigative Site

Wien, Austria, 1090

Status
Completed
Locations

Investigative Site

Graz, Austria, 8036

Status
Completed
Locations

Investigative Site

CRETEIL CEDEX, France, 94010

Status
Completed
Locations

Investigative Site

Praha 10, Czech Republic, 100 34

Status
Completed
Locations

Investigative Site

Hradec Kralove, Czech Republic, 500 05

Status
Completed
Locations

Investigative Site

Southampton, United Kingdom, SO16 6YD

Status
Completed
Locations

Investigative Site

Sunderland, United Kingdom, SR2 9HP

Status
Completed
Locations

Investigative Site

Leeds, United Kingdom, LS9 7TF

Status
Completed
Locations

Investigative Site

London, United Kingdom, EC1V 2PD

Status
Completed
Locations

Investigative Site

Gdansk, Poland, 80-809

Status
Completed
Locations

Investigative Site

Lublin, Poland, 20-081

Status
Completed
Locations

Investigative Site

Krakow, Poland, 31-501

Status
Completed
Locations

Investigative Site

Bydgoszcz, Poland, 85-631

Status
Completed
Locations

Investigative Site

Warszawa, Poland, 01-013

Status
Completed
Locations

Investigative Site

Poznan, Poland, 61-285

Status
Completed
Locations

Investigative Site

Warszawa, Poland, 04-141

Status
Completed
Locations

Investigative Site

Lodz, Poland, 91-134

Status
Completed
Locations

Investigative Site

Katowice, Poland, 40-594

Status
Completed
Locations

Investigative Site

Genova, Italy, 16132

Status
Completed
Locations

Investigative Site

Sassari, Italy, 07100

Status
Completed
Locations

Investigative Site

Torino, Italy, 10122

Status
Completed
Locations

Investigative Site

Roma, Italy, 00133

Status
Completed
Locations

Investigative Site

Milano, Italy, 20122

Status
Completed
Locations

Investigative Site

Firenze, Italy, 50134

Status
Completed
Locations

Investigative Site

Milano, Italy, 20132

Status
Completed
Locations

Investigative Site

Cagliari, Italy, 09124

Status
Completed
Locations

Investigative Site

Padova, Italy, 35128

Status
Completed
Locations

Investigative Site

Barcelona, Spain, 08036

Status
Completed
Locations

Investigative Site

L'Hospitalet de Llobregat, Spain, 08907

Status
Completed
Locations

Investigative Site

Barcelona, Spain, 08035

Status
Completed
Locations

Investigative Site

Albacete, Spain, 02006

Status
Completed
Locations

Investigative Site

Valencia, Spain, 46014

Status
Completed
Locations

Investigative Site

Sant Cugat del Vallés, Spain, 08195

Status
Completed
Locations

Investigative Site

Leiria, Portugal, 2410-197

Status
Completed
Locations

Investigative Site

Lisboa, Portugal, 1649-035

Status
Completed
Locations

Investigative Site

Vila Franca de Xira, Portugal, 2600-178

Status
Completed
Locations

Investigative Site

Coimbra, Portugal, 3000-548

Status
Completed
Locations

Investigative Site

Porto, Portugal, 4200-319

Status
Completed
Locations

Investigative Site

Budapest, Hungary, 1085

Status
Completed
Locations

Investigative Site

Budapest, Hungary, 1133

Status
Completed
Locations

Investigative Site

Debrecen, Hungary, 4032

Status
Completed
Locations

Investigative Site

Pecs, Hungary, 7621

Status
Completed
Locations

Investigative Site

Budapest, Hungary, 1106

Status
Completed
Locations

Investigative Site

Zvolen, Slovakia, 960 01

Status
Completed
Locations

Investigative Site

Bratislava, Slovakia, 851 07

Status
Completed
Locations

Investigative Site

Nitra, Slovakia, 949 01

Status
Completed
Locations

Investigative Site

Bratislava, Slovakia, 826 06

Status
Completed
Locations

Investigative Site

Zilina, Slovakia, 01207

Status
Completed
Locations

Investigative Site

Kaunas, Lithuania, LT-50009

Status
Completed
Locations

Investigative Site

Vilnius, Lithuania, LT-08661

Status
Completed
Locations

Investigative Site

Bern, Switzerland

Status
Completed
Locations

Investigative Site

Genève, Switzerland, 1204

Status
Completed

Trial Design